Mission and Vision

​​Investment in clinical research represents investment in a healthier society. Clinical research conducted at a major medical center complements university based pre-clinical research because the questions being asked arise directly from the clinical setting and proceed rapidly to the lab bench for translation to the patient’s bedside. Physicians involved in rigorous, high-level, clinically relevant research are closely familiar with the most up-to-date therapeutic modalities and trials.
Rambam Health Care Campus established the Clinical Research Institute at Rambam (CRIR) in 2008. The institute is rapidly fulfilling its aim to become a benchmark for clinical research excellence in Israel and worldwide by combining first-rate innovative research with high-quality patient care.
The clinician-scientists of the CRIR also have active Rambam Health Care Campus appointments in clinical divisions and departments. Rambam physicians wishing to participate in clinical research are encouraged to collaborate with CRIR researchers, whose willingness and track record for engaging clinicians in research is an important criterion in their recruitment.
A rigorous and competitive recruitment process together with scientific oversight by an in-house Scientific Working Group and an international Scientific Advisory Board (SAB) ensure that CRIR research meets uncompromising scientific standards. Entrusted with leadership of the Scientific Working Group are Professor Rafi Beyar, Director and CEO, Rambam Health Care Campus (HCC); Professor Karl Skorecki, Director of Medical and Research Development, Rambam HCC; and Professor Yehuda Chowers, Director, Research Division, Rambam HCC.
A matching grant from the American Friends of Rambam Medical Center (AFORAM) has enabled the CRIR leadership team to get this project off the ground. Donor funding is sought to help establish additional CRIR Research Centers of Excellence and to provide Clinical Research Fellowships for graduate students and clinicians.
In the future, licensing of novel diagnostic and therapeutic modalities emanating from the CRIR, together with significant external grants and other revenue streams, will help support the Institute's long-term operating costs and sustain its growth and development.